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Abstract
Background: Pulmonary metastases occur in up to 25% of colorectal cancer (CRC) patients. Many studies have
reported that pulmonary metastasectomy might increase 5-year survival of these patients. The aim of this study was
to describe our experience with pulmonary metastasectomy for metastatic colorectal cancer and to explore the
prognostic value of p53 overexpression and other factors.
Methods: Between July 2002 and December 2013, the clinicopathological data of 88 patients with colorectal carcinoma
who underwent pulmonary metastases resection were retrospectively reviewed and analyzed. Clinical, biochemical and
imaging, and operative data, and expression of p53 were retrospectively collected. Immunohistochemical staining for p53
was performed on paraffin-embedded 5-μm sections using mouse anti-human tumor protein p53 monoclonal antibody
(DO-7, Dako, Denmark). Overall survival (OS) was calculated from resection of pulmonary metastases to death. The
prognostic effect of each variable on survival was evaluated using the Kaplan-Meier method and log-rank test. For the
multivariate analysis of prognostic factors, the Cox regression model was used.
Results: There were 58 men and 30 women in this study, and their median age was 55 (range 31 to 85). Video-assisted
thoracoscopic surgery (VATS) was performed in 59 cases (78%), and 29 patients (19%) underwent thoracotomy. Lung
wedge resection and pulmonary lobectomy were performed in 52 (59.1%) and 36 (40.9%) patients, respectively. After a
median follow-up duration of 44 months, the cumulative 5-year survival was 45.4%, and the median overall survival was
57.8 months. The expression of p53 significantly influenced survival. In patients with p53 protein overexpression, we
observed a median OS of 46.1 months, whereas the median OS of patients with negative protein expression of p53 was
62.6 months (p = 0.047). However, in multivariate analysis, p53 overexpression was failed to be an independently
significant prognostic factor for survival.
Conclusions: Pulmonary resection of metastatic colorectal cancer might offer a chance to prolong survival including those
patients with extrapulmonary metastases. p53 protein expression was identified as a prognosis-related factor for surgery.
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Background
Colorectal cancer (CRC) is the third most common malig-
nancy all round the world [1]. At least 50% of CRC pa-
tients will develop a metastatic disease and about 5–25%
of them are located in the lung [2]. Due to the develop-
ment of new chemotherapeutic drugs and minimal inva-
sive video-assisted thoracoscopy and the fact that liver
metastasectomy contributes to survival improvement, pul-
monary metastasectomy has emerged as a potentially
curative option in the multimodal management of meta-
static CRC [2, 3]. When compared with 5% for patients
without pulmonary metastasis local treatment, the re-
ported 5-year survival of CRC can be elevated up to 62%
after pulmonary metastasectomy [4]. Since the 1990s, a
large number of retrospective studies have shown that
multiple clinical features may be probable prognostic sur-
vival factors for patients after metastasectomy, such as the
number of metastases, preoperative carcinoembryonic
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antigen serum (CEA) level, thoracic lymph node involve-
ment, and surgical procedures [4–8]. However, reliable
and objective prognostic variables are still in urgent need
of distinguishing patients who benefit from a surgical ap-
proach [2, 4]. As a common tumor suppressor, p53 over-
expression is thought to be a probable prognostic factor
and response to therapy. Nevertheless, the prognostic
value of p53 overexpression in CRC patients after pul-
monary metastasectomy was investigated in few studies.
Therefore, the objective of this retrospective study was to
describe our experience in pulmonary metastasectomy for
metastatic CRC and explore whether p53 overexpression
has prognostic value in pulmonary metastasectomy of
CRC.
Methods
Between July 2002 and December 2013, 88 patients under-
went resection of pulmonary metastases from colorectal
cancer. Each patient had a proven tissue diagnosis of
metastatic colorectal adenocarcinoma. The criteria for re-
section of pulmonary metastases included unilateral or bi-
lateral resectable lung lesions, no local recurrence of
primary lesions, and adequate cardiorespiratory function
for complete resection of all pulmonary lesions. Extrapul-
monary metastases of light tumor burden were included.
Clinical, biochemical and imaging, and operative data
were collected from computerized records. Immunohisto-
chemical (IHC) staining for p53 was performed on
paraffin-embedded 5-μm sections using mouse anti-
human tumor protein p53 monoclonal antibody (DO-7,
Dako, Denmark). Samples were considered positive when
at least 20% of the cancer cells were positive for p53 stain-
ing. Follow-up data were obtained from the patients’ re-
cords and by contacting the patients’ respective general
practitioners. The data were analyzed by SPSS 13.0 ver-
sion. The prognostic effect of each variable on survival
was evaluated using the Kaplan-Meier method and log-
rank test. For the multivariate analysis of prognostic fac-
tors, the Cox regression model was used. P value of less
than 0.05 was considered statistically significant.
Results
Patient characteristics
The study included 58 men (65.9%) and 30 women
(34.1%), and the median age was 55 years (range 31 to
85 years). The primary tumor location included 25
(28.4%) in the colon and 63 (71.6%) in the rectum. Pul-
monary metastasis was solitary in 71 patients (80.7%)
and multiple in 17 patients (19.3%, unilateral in 5, bilat-
eral in 12). Five patients had extrapulmonary metastases,
including two solitary liver metastases (one of them had
liver metastases resection after pulmonary metastasect-
omy), one thoracic lymph node metastasis, one pelvic
soft tissue metastasis, and one pleura metastasis, and
none of them received treatment for metastasis. Fifty-
nine patients (67%) underwent palliative chemotherapy,
and the common regimens were irinotecan-based or
oxaliplatin-based combined chemotherapy. Among
them, 24 patients (27.3%) underwent more than one line
chemotherapy. Video-assisted thoracoscopic surgery
(VATS) was performed in 59 cases (78%) and thoracot-
omy in 29 patients (19%). Fifty-two patients (59.1%)
underwent lung wedge resection, and 36 patients
(40.9%) underwent pulmonary lobectomy (Table 1).
We also analyzed the correlation between p53 expres-
sion level and clinicopathological factors, but none of
them has significant relationship with p53 status
(Table 2).
Survival analysis
Median follow-up duration was 44 months (range 3 to
162 months). The median interval between CRC diagno-
sis and lung metastasis diagnosis was 25 months (range
0 to 122 months). After pulmonary metastasectomy, dis-
ease recurrence was identified in 26 of the 88 patients
(distant metastasis in 7, local recurrence in 19). The
interval between pulmonary metastasectomy and disease
recurrence had a median of 13.5 months (range 4.2 to
34.8 months). At the last follow-up, 51 patients (58.0%)
were alive and the cumulative 5-year survival was 45.4%,
and the median survival was 57.8 months.
Among the analyzed prognostic factors, age, gender,
maximum tumor size of lung metastasis, localization of
the primary tumor, metastases phase, and the number of
lung metastasis, extrapulmonary metastases and preopera-
tive CEA level did not influence survival significantly.
However, p53 overexpression greatly affected survival. In
patients with negative p53 expression, an overall survival
of 62.6 months was observed, whereas an overall survival
of 46.1 months was observed in patients with positive p53
expression (p = 0.047) (Table 1, Fig. 1). Furthermore, re-
peated analysis in patients with solitary or multiple lung
metastases showed the prognostic value of p53 protein ex-
pression. However, p53 was not confirmed to be an inde-
pendently significant prognostic factor for survival in
multivariate analysis (p = 0.051).
Discussion
Even though there is no randomized trial evidence, re-
section of pulmonary metastases is considered to be an
effective measure to improve the survival of the appro-
priately selected CRC patients with lung metastases.
Multiple studies have evaluated a number of possible
clinical or pathological prognostic indicators. However,
the relationship between molecular abnormalities and
survival is unclear [5, 9–12].
As a tumor suppressor gene, p53 is a common target
of genetic alteration in human cancer [13, 14], which
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exerts the function of controlling the induction of
growth arrest and apoptosis by eliminating damaged
cells [15, 16]. Alteration of this gene is associated with
postoperative outcome and poor prognosis [17]. Tech-
nically, p53 protein expression can be assessed by IHC
and p53 genomic status can be analyzed using direct
gene sequencing [18]. In consideration of its technical
reproducibility and high concordance with that of gen-
omic analysis, IHC still holds considerable promise as a
convenient and inexpensive means [18]. Therefore, IHC
was adopted as a method to assess the p53 expression in
this study.
Previous studies have revealed p53 protein expression
with the help of IHC in 42–69% of CRCs [15, 16, 18].
Multiple tumors with increased p53 expression were as-
sociated with lymph node metastasis, extrathyroidal in-
vasion, pleural infiltration, and tumor location [19, 20].
Literature review showed that p53 overexpression could
be an adverse independent predictor of survival [21, 22].
In addition, p53 expression was found to be related to
liver metastases of colorectal tumors in some studies
[23–25]. However, some investigations failed to docu-
ment a significant inverse correlation of p53 overexpres-
sion with CRC patients’ survival after pulmonary
metastasectomy. One possible reason was that there
were so many variables related to staining protocols and
scoring systems that contrasting results were provided
Table 1 Clinical and pathological characteristics of 88 patients
and univariate analysis for OS
Factor Number (%) OS (months) p value
Age (years)
≤60 61 (69.3) 57.8 0.475
>60 27 (30.7) 55.6
Gender
Male 58 (65.9) 57.8 0.729
Female 30 (34.1) 67.9
Tumor size of lung metastasis (cm)
≤3 75 (85.2) 62.6 0.212
>3 13 (14.8) 47.2
Primary tumor localization
Left-sided colon 9 (10.2) 41.2 0.185
Right-sided colon 16 (18.2) 67.9
Rectum 63 (71.6) 61.6
Metastases phase
Synchronous metastases 10 (11.4) 46.1 0.661
Metachronous metastases 78 (88.6) 57.8
Pulmonary metastases number
Single 71 (80.7) 62.6 0.23
Multiple 17 (19.3) 49.8
Extrapulmonary metastasis
Yes 5 (5.7) 39.5 0.756
No 83 (94.3) 57.8
Surgical procedures
VATS 59 (67.0) 62.6 0.516
Thoracotomy 29 (33.0) 57.8
Resection range
Lung wedge resection 52 (59.1) 67.9 0.696
Pulmonary lobectomy 36 (40.9) 57.8
Preoperative CEA level
Normal 64 (72.7) 62.6 0.142
Elevated 24 (27.3) 42
p53 IHC
Positive 42 (47.7) 46.1 0.047
Negative 46 (52.3) 62.6
IHC immunological histological chemistry, CEA carcinoembryonic antigen
Table 2 Relationship between p53 protein levels in colorectal
tumors and clinicopathological variables
Variable Number (%) p53 positive p53 negative p value
(n = 42) (n = 46)
Age Range 35–76 31–85 –
Median 53 55
Sex Male 29 29 0.654
Female 13 17
T status T1-2 9 8 0.788
T3-4 33 38
N status N0 17 27 0.135
N+ 25 19
Site Left colon 5 4 0.851
Right colon 7 9
Rectum 30 33
Preoperative CEA <5ng/ml 28 36 0.241
>5ng/ml 14 10
Fig. 1 Probability of survival of patients with positive expression of
p53 vs patients with negative expression (p = 0.047)
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[26]. More importantly, the relationship between p53
overexpression and gene alteration was actually compli-
cated [27]. Protein overexpression is seen in gene muta-
tion type and cases with wild type [26, 28]. Generally,
different kinds of antibodies mainly recognize certain
mutants or wild type of genes, which cannot fully reflect
protein expression to some extent.
In this study, p53 overexpression was shown in 42
(47.7%) cases with a significantly shorter survival (me-
dian OS 62.6 vs 42.1 months, p = 0.046), which sug-
gested a potential candidate for modulating the risk of
colorectal lung metastases of p53. However, a single-
center retrospective design and highly selected patient
population could have introduced biased information.
Additionally, the small size of the population and the
co-linear relation between the parameters may give rise
to meaningless results of multivariate analysis. There-
fore, a larger trial is needed to confirm the value of p53
overexpression or mutation.
Conclusions
In conclusion, surgical resection of pulmonary metasta-
ses may extend the survival of CRC patients even if
there are extrapulmonary metastases. Besides, p53 over-
expression may help judge the prognosis of patients who
undergo pulmonary metastasectomy.
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